Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab
Psoriasis is a chronic inflammatory disease with a prevalence of approximately 2-3% in the general population. The majority of diagnosed patients have plaque psoriasis, and about 20% have moderate-to-severe disease. Itolizumab, a new monoclonal antibody specific for the CD6 molecule mainly expressed on T lymphocytes, has demonstrated to inhibit in vitro ligand-induced proliferation and pro-inflammatory cytokine production. We assessed the immunological and histopathological effect of the antibody using clinical samples taken from 26 patients with moderate-to-severe psoriasis included in a clinical trial. The precursor frequency of lymphocytes activated with anti-CD2/CD3/CD28 beads, as well as the number of interferon (IFN)-γ-secreting T cells after stimulation, were measured at different time points of the study. Serum cytokine levels and anti-idiotypic antibody response to itolizumab were also evaluated. Additionally, lymphocyte infiltration and epidermis hyperplasia were studied in five patients. A significant reduction in T cell proliferation capacity and number of IFN-γ-producing T cells was found in treated patients. Serum levels of interleukin-6, tumor necrosis factor and IFN-γ showed an overall trend toward reduction. No anti-idiotypic antibody response was detected. A significant reduction in the epidermis hyperplasia was observed in analyzed patients. These results support the relevance of the CD6 molecule as a therapeutic target for the treatment of this disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
mAbs - 6(2014), 3 vom: 26. Mai, Seite 783-93 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aira, Lazaro E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.05.2015 Date Revised 21.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.4161/mabs.28376 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM236085778 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM236085778 | ||
| 003 | DE-627 | ||
| 005 | 20231224104813.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4161/mabs.28376 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0787.xml |
| 035 | |a (DE-627)NLM236085778 | ||
| 035 | |a (NLM)24594862 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aira, Lazaro E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Immunological and histological evaluation of clinical samples from psoriasis patients treated with anti-CD6 itolizumab |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2015 | ||
| 500 | |a Date Revised 21.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Psoriasis is a chronic inflammatory disease with a prevalence of approximately 2-3% in the general population. The majority of diagnosed patients have plaque psoriasis, and about 20% have moderate-to-severe disease. Itolizumab, a new monoclonal antibody specific for the CD6 molecule mainly expressed on T lymphocytes, has demonstrated to inhibit in vitro ligand-induced proliferation and pro-inflammatory cytokine production. We assessed the immunological and histopathological effect of the antibody using clinical samples taken from 26 patients with moderate-to-severe psoriasis included in a clinical trial. The precursor frequency of lymphocytes activated with anti-CD2/CD3/CD28 beads, as well as the number of interferon (IFN)-γ-secreting T cells after stimulation, were measured at different time points of the study. Serum cytokine levels and anti-idiotypic antibody response to itolizumab were also evaluated. Additionally, lymphocyte infiltration and epidermis hyperplasia were studied in five patients. A significant reduction in T cell proliferation capacity and number of IFN-γ-producing T cells was found in treated patients. Serum levels of interleukin-6, tumor necrosis factor and IFN-γ showed an overall trend toward reduction. No anti-idiotypic antibody response was detected. A significant reduction in the epidermis hyperplasia was observed in analyzed patients. These results support the relevance of the CD6 molecule as a therapeutic target for the treatment of this disease | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CD6 | |
| 650 | 4 | |a anti-idiotypic antibody response | |
| 650 | 4 | |a cell proliferation | |
| 650 | 4 | |a epidermal hyperplasia | |
| 650 | 4 | |a itolizumab | |
| 650 | 4 | |a pro-inflammatory cytokines | |
| 650 | 4 | |a psoriasis | |
| 650 | 7 | |a Antibodies, Anti-Idiotypic |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a Antigens, Differentiation, T-Lymphocyte |2 NLM | |
| 650 | 7 | |a CD6 antigen |2 NLM | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Interferon-gamma |2 NLM | |
| 650 | 7 | |a 82115-62-6 |2 NLM | |
| 650 | 7 | |a itolizumab |2 NLM | |
| 650 | 7 | |a XQQ2RHV14N |2 NLM | |
| 700 | 1 | |a López-Requena, Alejandro |e verfasserin |4 aut | |
| 700 | 1 | |a Fuentes, Dasha |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez, Liset |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez, Teresita |e verfasserin |4 aut | |
| 700 | 1 | |a Urquiza, Aleida |e verfasserin |4 aut | |
| 700 | 1 | |a Bautista, Heber |e verfasserin |4 aut | |
| 700 | 1 | |a Falcón, Leopoldina |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, Patricia |e verfasserin |4 aut | |
| 700 | 1 | |a Mazorra, Zaima |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mAbs |d 2009 |g 6(2014), 3 vom: 26. Mai, Seite 783-93 |w (DE-627)NLM194097110 |x 1942-0870 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2014 |g number:3 |g day:26 |g month:05 |g pages:783-93 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.4161/mabs.28376 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2014 |e 3 |b 26 |c 05 |h 783-93 | ||